-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although new systemic anti-cancer therapies are constantly being developed, anthracyclines are still an important anti-cancer drug for many cancers.
Jones et al.
The tested patients were patients with locally advanced or metastatic soft tissue sarcoma who had not been treated with anthracyclines, and left ventricular ejection fraction (LVEF) ≥50%.
Changes in LVEF
Changes in LVEF504 patients received at least one cycle of doxorubicin therapy (median cumulative dose was 450.
Patients receiving higher cumulative doses of doxorubicin (38.
Adverse reactions
Adverse reactionsThe LVEF worsening rates of patients with cumulative doses <450 mg/m2, 450-<600 mg/m2, and ≥600 mg/m2 were 40.
The LVEF worsening rates of patients with cumulative doses <450 mg/m2, 450-<600 mg/m2, and ≥600 mg/m2 were 40.
In the case of combined use with the cardioprotective agent dexrazoxane, the cumulative dose of doxorubicin can be very high (>450 mg/m2), and the incidence of cardiotoxicity is low.
Original source:
Jones Robin L, Wagner Andrew J, Kawai Akira et al.
Leave a message here
